Objectives: evaluate the cost-effectiveness of the use of toric intraocular lenses (IOLs) in surgery of patients with cataract and preexisting corneal astigmatism (> 0.75 D), versus the use of traditional monofocal intraocular lenses (IOLs) from the perspective of third party payer, as a way to define which technology could considered in the health care reimbursement. MethOds: in a decision tree type model was simulated the cataracts surgery intervention in a time horizon of five years. The outcome measure was the cumulative visual acuity of 20/32, which was expressed in normal vision time without additional support. The drug costs were taken from SISMED (2013), the costs from multi-core procedures of the health ministry (SISPRO), the cost of glasses and contact lenses from commercial channel, and the cost of IOLs were taken as the selling price of Alcon Laboratories. Finally a Montecarlo type sensitivity analysis was performed. Results: as primary outcome, time normal distance vision without additional support was higher with toric IOLs, which it were more effective at 3,64 years versus 2,97 years achieved with traditional monofocal IOLs. Intervention with toric IOLs showed in the time horizon of five years be more expensive with (USD) $1.093,55 versus costs of traditional monofocal IOLs (USD) $732,71. In this regard cataract surgery is more effective and more costly with toric IOLs than with traditional monofocal IOLs with an incremental cost-effectiveness ratio of (USD) $534,83 per each year of normal vision without additional support. It was observed that the ICER improves if there is a greater visual impairment due to astigmatism before surgery, as well, to diopters < 1.50, > 1.50 < 2.00 and > 2.00 the ICER was (USD) $ 712.40, (USD) $ 416.75 and (USD) $ 382.16 respectively. cOnclusiOns: toric IOLs proved to be cost-effective for the treatment of patients with cataract and preexisting astigmatism.
Objectives: To evaluate the cost effectiveness, from the Colombian health care system perspective, of ranibizumab monotherapy or ranibizumab combined with laser against laser monotherapy for the treatment of diabetic macular edema (DME). MethOds: A Markov model was designed to simulate the clinical and economic benefits associated with ranibizumab as either monotherapy or combined with laser versus laser monotherapy in the treatment of visual impairment due to DME. The effectiveness outcomes measured were the life years without visual impairment based on RESTORE 3-year follow-up data. Over 15-year time horizon annual cycles were performed. The costs involved in the model were taken from the official medication cost database in Colombia (SISMED) and 6 Colombian health care providers (IPS) The analysis, according to the RESTORE study, considered that 22 % of patients received treatment on both eyes. For ranibizumab and laser group, the first three years transition probabilities where taken from the same study and for the laser group the second and third year data was taken from the Diabetic Retinopathy Clinical Research Network (DRCR.net ). Results: Ranibizumab monotherapy showed a gain of 0.30 years with no visual impairment at an incremental cost of COP 8, 272, 248 (USD 4.273, 01) relative to laser monotherapy, resulting in an incremental cost-effectiveness ratio (ICER) of COP 28, 041, 494 (USD $14.484, 77) . Likewise ranibizumab monotherapy was superior to combination therapy with an ICER of COP 34, 224, 675 (USD $17.678, 67) in a time horizon of 15 years. Probabilistic sensitivity analysis placed ranibizumab monotherapy as a more cost-effective alternative versus laser monotherapy in 95% of the cases. cOnclusiOns: The results pointed out that ranibizumab both as a monotherapy as well as combined with laser therapy are cost-effective alternatives from the Colombian health care system perspective.
PSS21 USing A CrOSSOvEr StUdy dESign fOr EArly hOSPitAl-bASEd hEAlth tEChnOlOgy ASSESSmEnt: thE COSt-EffECtivEnESS Of CliniC-bASEd ChlOrAl hydrAtE SEdAtiOn vErSUS gEnErAl AnAESthESiA fOr PAEdiAtriC OPhthAlmOlOgiCAl PrOCEdUrES
Burnett H. F. , Lambley R. , West S. , Mireskandari K. , Ungar W. J. Hospital for Sick Children, Toronto, ON, Canada Objectives: Hospitals are a favorable environment for early health technology assessment (HTA) and cross-over designs are ideally suited for this. For example, young children who cannot tolerate eye examinations may require examination under anesthesia (EUA) in an operating room. Examination under chloral hydrate sedation (EUS) in an outpatient clinic may be a convenient and cost-effective alternative. The objective was to determine the incremental cost of EUS compared to EUA per additional successful procedure gained from a societal perspective. MethOds: A cost-effectiveness analysis was conducted using a retrospective cross-over cohort of 80 children that had both EUS and EUA. Direct costs included health professional services, supplies and equipment and indirect costs included parent productivity losses. Outcomes included the number of successful procedures and adverse events (AEs). One-way and probabilistic sensitivity analyses were conducted. Results: The mean cost per patient was $406 (95% CI $401, $411) for EUS and $1,135 (95% CI $1,125, $1,145) for EUA. The mean number of successful procedures per patient was 1.39 (95% CI 1.34, 1.42) for EUS and 2.06 (95% CI 2.02, 2.11) for EUA. EUS was $729 less costly on average than EUS but resulted in 0.68 fewer successful procedures per child. Three AEs occurred in 2 EUS patients compared to 1 in the EUA group. The result was robust to varying Objectives: Retinitis Pigmentosa (RP) is a hereditary genetic disease causing bilateral retinal degeneration. RP is a leading cause of blindness resulting in incurable visual impairment and drastic reduction in the Quality of life of the patients. Although the condition is at present incurable, advances in the field of retinal implants demonstrate the progress now being made in combating the condition and restoring a measure of sight to those afflicted. The objective of this study was to assess the cost-effectiveness of first ever-commercial implant intended to restore some vision in the Retinitis Pigmentosa (RP) patients. MethOds: A multi -state transition Markov model was developed to determine the cost-effectiveness of retinal transplant versus usual care in RP from the perspective of health care payer. A hypothetical cohort of 1000 RP patients aged 46 years followed up over a (lifetime) 25-year time horizon. Health outcomes were expressed as quality adjusted life years (QALYs) and direct health care costs expressed in 2012 € . Results are reported as incremental cost per ratios (ICERs) with outcomes and costs discounted at an annual rate of 3.5%. Results: The ICER for the retinal implant was € 14,603 /QALY. Taking into account the uncertainty in model inputs the ICER was € 14,482/QALY in the probabilistic analysis. In the scenarios of an assumption of no reduction on cost across model visual acuity states or a model time horizon as short as 10 years the ICER increased to € 31,890/QALY and € 49,769/ QALY respectively. cOnclusiOns: This economic evaluation shows that the retinal implant is a cost-effective intervention compared to usual care of the RP patients. The ICER for retinal implant falls below the published societal willingness to pay of EuroZone countries. Retinal implants could eventually change the lives of up to 200,000 people worldwide who suffer from blindness due to Retinitis Pigmentosa.
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COSt-EffECtivEnESS AnAlySiS Of OPhthAlmiC PrOStAglAndin AnAlOgUES fOr thE mAnAgEmEnt Of OCUlAr hyPErtEnSiOn And glAUCOmA
Lin L. , Zhao Y. J. , Khoo A. L. , Teng M. , Lim B. P. Pharmacy & Therapeutics Office, Corporate Development, National Healthcare Group, Singapore, Singapore Objectives: Prostaglandin analogues (PGAs) lower ophthalmic intraocular pressure (IOP) and are widely used as first-line therapies in the management of ocular hypertension (OH) or primary open-angle glaucoma (POAG). They are more costly than alternative agents and this may impose a financial burden on patients as treatment is life-long. This study sought to evaluate the cost-effectiveness of four PGAs, bimatoprost, latanoprost, tafluprost and travoprost, as first-line monotherapy in patients with OH or POAG to inform formulary decision on the optimal agents to stock in a local hospital. MethOds: A decision-analytic model was developed to simulate a cohort of patients with OH or POAG receiving PGA or timolol treatment over a one-month time horizon. The effectiveness data used were the proportion of patients achieving a clinical target of at least a 30% reduction in IOP from baseline and the incidence of hyperemia, a common side effect of PGAs. Treatment success and hyperemia rates were extracted from published literature and synthesised using a network meta-analysis. Cost of medications and doctor visits were included, in accordance with the adopted patient's perspective, and this information was obtained from the hospital. The results were expressed as incremental cost per additional patient achieving clinical success. Deterministic sensitivity analyses were conducted to assess the robustness of the results. Results: Latanoprost and bimatoprost had a positive incremental cost-effectiveness ratio (ICER) of SGD 168 and SGD 200, respectively, relative to timolol. Both travoprost and tafluprost were dominated by latanoprost. The results were most sensitive to the proportion of patients achieving at least a 30% IOP reduction from baseline and the cost of medications. cOnclusiOns: This analysis suggests that latanoprost and bimatoprost are preferred among the four PGAs in terms of cost-effectiveness. Cost-effectiveness should be considered alongside other factors including comparative clinical efficacy and safety to make an informed formulary decision.
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COSt-EffECtivEnESS AnAlySiS Of inSUrEd EyE CArE SErviCES by OPtOmEtriStS in PrinCE EdWArdS iSlAnd (PEi): An ExAmPlE Of diAbEtiC rEtinOPAthy mAnAgEmEnt
Tu H. A. T. , Wedge R. , Yaping J. , Trope G. , El-Defrawy S. , Flanagan J. , Buys Y. M. , Thavorn K.
University of Toronto, Toronto, Canada
Objectives: Optometric services are not publicly funded in Prince Edward Island (PEI). This analysis aimed to assess the cost-effectiveness of funding optometrists for diabetic eye care versus funding general practitioners (GPs) for such services in PEI using PEI government's health care payer perspective. MethOds: A Markov cohort model of diabetic retinopathy (DR) was developed using PEI disease data (diabetic incidence, DR incidence and mortality), PEI cost data, and the data from the literature (utilities, DR progression). In the base-case, biannual screening of DR was assumed. A hypothetical cohort of diabetic patients of 35 years and older in PEI (8,392) was simulated to estimate expected lifetime health outcomes (nonproliferative cases, proliferative cases, mortality, quality-adjusted life years (QALYs)) and cost (screening cost, treatment of proliferation retinopathy). Primary outcomes were expected QALYs, cost and incremental cost per QALY gained. Sensitivity analyses were conducted to examine the robustness of the results. QALYs and costs were discounted at 5%. Results: In the base-case, biannual screening and treatment of DR by optometrists was determined as a cost-saving strategy compared to GP delivered service. The model was most sensitive to the health utility of diabetic patients, and screening rates provided by GPs. Varying the discount rate from 0 to 5% had the least impact on the cost-effectiveness of screening results. In other screening scenarios (annual and biennial), services provided by optometrists appeared to be very cost-effective, or even cost-savings compared to services delivered by GPs. The estimated potential financial savings to PEI government could be between Canadian dollar (C$) 45,000 to C$390,000 during 1 year to 10-year horizon if optometric services were publicly funded. cOnclusiOns: Publicly funded screening and treatment of DR by optometrists in PEI is potentially a cost-saving strategy compared to the usual care provided by GPs.
